Thyroid transcription factor-1 expression is an independent predictor of recurrence and correlates with the IASLC/ATS/ERS histologic classification in patients with stage i lung adenocarcinoma

Cancer

Volumn 119, Issue 5, 2013, Pages 931-938

  Kadota, Kyuichi ^a,b   Nitadori, Jun Ichi ^a   Sarkaria, Inderpal S ^a   Sima, Camelia S ^a   Jia, Xiaoyu ^a   Yoshizawa, Akihiko ^c   Rusch, Valerie W ^a   Travis, William D ^a   Adusumilli, Prasad S ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b KAGAWA UNIVERSITY   (Japan)

^c SHINSHU UNIVERSITY HOSPITAL   (Japan)

Author keywords

histologic subtype; lung adenocarcinoma; recurrence.; thyroid transcription factor 1

Indexed keywords

THYROID TRANSCRIPTION FACTOR 1;

ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER INCIDENCE; CANCER INVASION; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENE EXPRESSION; GENE IDENTIFICATION; GENETIC CORRELATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCORING SYSTEM; TISSUE MICROARRAY; TTF 1 GENE;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NUCLEAR PROTEINS; RECURRENCE; RETROSPECTIVE STUDIES; TRANSCRIPTION FACTORS;

EID: 84874274525     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.27863     Document Type: Article

References (37)

1. Siegel R, Ward E, Brawley O, Jemal A,. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011; 61: 212-236.
2. Rusch VW, Appelman HD, Blackstone E, et al. Lung. In: Edge SB, Byrd DR, Compton CC, et al, editors. AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer; 2009: 253-270.
3. Goldstraw P, Crowley J, Chansky K, et al. International Association for the Study of Lung Cancer International Staging Committee; Participating Institutions. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol. 2007; 2: 706-714.
4. Travis WD, Brambilla E, Noguchi M, et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol. 2011; 6: 244-285.
5. Yoshizawa A, Motoi N, Riely GJ, et al. Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases. Mod Pathol. 2011; 24: 653-664.
6. Kadota K, Suzuki K, D'Angelo SP, et al. Validation of the proposed IASLC/ATS/ERS international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol. 2011; 6 (suppl 2): S286.
7. Warth A, Muley T, Meister M, et al. The novel histologic International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification system of lung adenocarcinoma is a stage-independent predictor of survival. J Clin Oncol. 2012; 30: 1438-1446.
8. Ikeda K, Clark JC, Shaw-White JR, Stahlman MT, Boutell CJ, Whitsett JA,. Gene structure and expression of human thyroid transcription factor-1 in respiratory epithelial cells. J Biol Chem. 1995; 270: 8108-8114.
9. Puglisi F, Barbone F, Damante G, et al. Prognostic value of thyroid transcription factor-1 in primary, resected, non-small cell lung carcinoma. Mod Pathol. 1999; 12: 318-324.
10. Pelosi G, Fraggetta F, Pasini F, et al. Immunoreactivity for thyroid transcription factor-1 in stage I non-small cell carcinomas of the lung. Am J Surg Pathol. 2001; 25: 363-372.
11. Haque AK, Syed S, Lele SM, Freeman DH, Adegboyega PA,. Immunohistochemical study of thyroid transcription factor-1 and HER2/neu in non-small cell lung cancer: strong thyroid transcription factor-1 expression predicts better survival. Appl Immunohistochem Mol Morphol. 2002; 10: 103-109.
12. Myong NH,. Thyroid transcription factor-1 (TTF-1) expression in human lung carcinomas: its prognostic implication and relationship with expressions of p53 and Ki-67 proteins. J Korean Med Sci. 2003; 18: 494-500.
13. Tan D, Li Q, Deeb G, et al. Thyroid transcription factor-1 expression prevalence and its clinical implications in non-small cell lung cancer: a high-throughput tissue microarray and immunohistochemistry study. Hum Pathol. 2003; 34: 597-604.
14. Stenhouse G, Fyfe N, King G, Chapman A, Kerr KM,. Thyroid transcription factor 1 in pulmonary adenocarcinoma. J Clin Pathol. 2004; 57: 383-387.
15. Au NH, Cheang M, Huntsman DG, et al. Evaluation of immunohistochemical markers in non-small cell lung cancer by unsupervised hierarchical clustering analysis: a tissue microarray study of 284 cases and 18 markers. J Pathol. 2004; 204: 101-109.
16. Saad RS, Liu YL, Han H, Landreneau RJ, Silverman JF,. Prognostic significance of thyroid transcription factor-1 expression in both early-stage conventional adenocarcinoma and bronchioloalveolar carcinoma of the lung. Hum Pathol. 2004; 35: 3-7.
17. Barlesi F, Pinot D, Legoffic A, et al. Positive thyroid transcription factor 1 staining strongly correlates with survival of patients with adenocarcinoma of the lung. Br J Cancer. 2005; 93: 450-452.
18. Berghmans T, Mascaux C, Martin B, Ninane V, Sculier JP,. Prognostic role of thyroid transcription factor-1 in stage III non-small cell lung cancer. Lung Cancer. 2006; 52: 219-224.
19. Martins SJ, Takagaki TY, Silva AG, Gallo CP, Silva FB, Capelozzi VL,. Prognostic relevance of TTF-1 and MMP-9 expression in advanced lung adenocarcinoma. Lung Cancer. 2009; 64: 105-109.
20. Anagnostou VK, Syrigos KN, Bepler G, Homer RJ, Rimm DL,. Thyroid transcription factor 1 is an independent prognostic factor for patients with stage I lung adenocarcinoma. J Clin Oncol. 2009; 27: 271-278.
21. Barletta JA, Perner S, Iafrate AJ, et al. Clinical significance of TTF-1 protein expression and TTF-1 gene amplification in lung adenocarcinoma. J Cell Mol Med. 2009; 13: 1977-1986.
22. Perner S, Wagner PL, Soltermann A, et al. TTF1 expression in non-small cell lung carcinoma: association with TTF1 gene amplification and improved survival. J Pathol. 2009; 217: 65-72.
23. Anami Y, Iijima T, Suzuki K, et al. Bronchioloalveolar carcinoma (lepidic growth) component is a more useful prognostic factor than lymph node metastasis. J Thorac Oncol. 2009; 4: 951-958.
24. Tang X, Kadara H, Behrens C, et al. Abnormalities of the TITF-1 lineage-specific oncogene in NSCLC: implications in lung cancer pathogenesis and prognosis. Clin Cancer Res. 2011; 17: 2434-2443.
25. Solis LM, Behrens C, Raso MG, et al. Histologic patterns and molecular characteristics of lung adenocarcinoma associated with clinical outcome. Cancer. 2012; 118: 2889-2899.
26. Li X, Wan L, Shen H, et al. Thyroid transcription factor-1 amplification and expressions in lung adenocarcinoma tissues and pleural effusions predict patient survival and prognosis. J Thorac Oncol. 2012; 7: 76-84.
27. Chung KP, Huang YT, Chang YL, et al. Clinical significance of thyroid transcription factor-1 in advanced lung adenocarcinoma under epidermal growth factor receptor tyrosine kinase inhibitor treatment. Chest. 2012; 141: 420-428.
28. Sica G, Yoshizawa A, Sima CS, et al. A grading system of lung adenocarcinomas based on histologic pattern is predictive of disease recurrence in stage I tumors. Am J Surg Pathol. 2010; 34: 1155-1162.
29. Kadota K, Suzuki K, Kachala SS, et al. A grading system combining architectural features and mitotic count predicts recurrence in stage I lung adenocarcinoma. Mod Pathol. 2012; 25: 1117-1127.
30. Chappell R. Competing risk analyses: how are they different and why should you care? Clin Cancer Res. 2012; 18: 2127-2129.
31. Dignam JJ, Zhang Q, Kocherginsky M,. The use and interpretation of competing risks regression models. Clin Cancer Res. 2012; 18: 2301-2308.
32. Kaufmann O, Dietel M,. Thyroid transcription factor-1 is the superior immunohistochemical marker for pulmonary adenocarcinomas and large cell carcinomas compared to surfactant proteins A and B. Histopathology. 2000; 36: 8-16.
33. Saad RS, Cho P, Silverman JF, Liu Y,. Usefulness of Cdx2 in separating mucinous bronchioloalveolar adenocarcinoma of the lung from metastatic mucinous colorectal adenocarcinoma. Am J Clin Pathol. 2004; 122: 421-427.
34. Lau SK, Desrochers MJ, Luthringer DJ,. Expression of thyroid transcription factor-1, cytokeratin 7, and cytokeratin 20 in bronchioloalveolar carcinomas: an immunohistochemical evaluation of 67 cases. Mod Pathol. 2002; 15: 538-542.
35. Hurbin A, Wislez M, Busser B, et al. Insulin-like growth factor-1 receptor inhibition overcomes gefitinib resistance in mucinous lung adenocarcinoma. J Pathol. 2011; 225: 83-95.
36. Berghmans T, Paesmans M, Mascaux C, et al. Thyroid transcription factor 1-a new prognostic factor in lung cancer: a meta-analysis. Ann Oncol. 2006; 17: 1673-1676.
37. Rekhtman N, Ang DC, Sima CS, Travis WD, Moreira AL,. Immunohistochemical algorithm for differentiation of lung adenocarcinoma and squamous cell carcinoma based on large series of whole-tissue sections with validation in small specimens. Mod Pathol. 2011; 24: 1348-1359.